Esomeprazole Magnesium Capsule
NDC Package 73581-014-42
Package Information
Esomeprazole Magnesium capsules is adults 18 years of age and olderthis product is to be used once a day (every 24 hours), every day for 14 daysmay take 1 to 4 days for full effect14-Day Course of Treatment: swallow 1 capsule with a glass of water before eating in the morningtake every day for 14 daysdo not take more than 1 capsule a dayswallow whole. This formulation utilizes a capsule delivery system. Marketed by Yyba Corp, this product is identified by NDC 73581-014 and is authorized under FDA application ANDA209339.
Identification & Billing
- RxCUI: 606726 - esomeprazole magnesium 20 MG Delayed Release Oral Capsule
- RxCUI: 606726 - esomeprazole 20 MG Delayed Release Oral Capsule
- RxCUI: 606726 - esomeprazole 20 MG (as esomeprazole magnesium dihydrate 22 MG) Delayed Release Oral Capsule
- RxCUI: 606726 - esomeprazole 20 MG (as esomeprazole magnesium trihydrate 22.3 MG) Delayed Release Oral Capsule
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 73581 - Yyba Corp
- 73581-014 - Esomeprazole Magnesium
- 73581-014-42 - 3 BOTTLE in 1 CARTON / 14 CAPSULE in 1 BOTTLE
- 73581-014 - Esomeprazole Magnesium
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 73581-014-42 identifies a specific commercial package of 3 bottle in 1 carton / 14 capsule in 1 bottle of Esomeprazole Magnesium, a human over the counter drug labeled by Yyba Corp. This capsule is formulated for oral use and contains esomeprazole magnesium as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Yyba Corp on April 01, 2026. The current certification is valid through December 31, 2027.
How is this Yyba Corp product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 73581001442. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.